ESC 365 - Perspectives on the results of recent clinical outcome trials with icosapent ethyl

Open Access

Perspectives on the results of recent clinical outcome trials with icosapent ethyl

Session: Improving the management of patients with atherosclerotic cardiovascular disease: the evolving role of icosapent ethyl

Topic: Lipid-Lowering Agents

Speaker: Professor P. Steg (Paris, FR)

Sponsored by PACE-CME – Supported by an unrestricted educational grant from Amarin

Event: ESC Congress 2023

Congress Presentation

About the speaker

Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

66 presentations

10 followers

4 more presentations in this session

Introduction

Speaker: Professor P. Libby (Boston, US)

Challenges in atherosclerotic cardiovascular disease reduction and triglyceride-related risk

Speaker: Professor E. Stroes (Amsterdam, NL)

Integrating icosapent ethyl in cardiovascular risk reduction strategies: practical guidance

Speaker: Doctor P. Taub (La Jolla, US)

Discussion

Speaker: Professor P. Libby (Boston, US) Professor E. Stroes (Amsterdam, NL) Professor P. Steg (Paris, FR) Doctor P. Taub (La Jolla, US)

Access the full session

Improving the management of patients with atherosclerotic cardiovascular disease: the evolving role of icosapent ethyl

Speakers: Professor P. Steg, Professor P. Libby, Professor E. Stroes, Doctor P. Taub, Professor P. Libby...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources